Skip to main content
OpenTrials
Completed

NCT Number: NCT07266818

A Clinical Trial of MK-1167 in Healthy Adults (MK-1167-010)

The goal of this trial is to learn about the safety of MK-1167 and if people tolerate it.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Healthy

Age range

18 year–60 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Hassman Research Institute Marlton Site ( Site 0001)

Marlton, New Jersey, 08053, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

The key inclusion criteria but are not limited to the following:

  • Is in good health
  • Has a body mass index (BMI) ≥18 and ≤32 kg/m^2, inclusive

The key inclusion criteria but are not limited to the following:

  • Has a history of clinically significant endocrine, gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological abnormalities or diseases
  • Is a smoker and/or has used nicotine or nicotine-containing products (for example, nicotine patch and electronic cigarette) within the past 3 months

Treatment and study plan

MK-1167

Drug

Oral capsule administered once daily

Placebo

Drug

Oral capsule administered once daily

Primary outcomes

  1. Number of Participants Who Experience an Adverse Event (AE)

    Time frame: Up to approximately 9 weeks

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experience an AE will be reported.

  2. Number of Participants Who Discontinue Study Treatment Due to an AE

    Time frame: Up to approximately 1 week

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinue study treatment due to an AE will be reported.

Sponsors and collaborators

Lead sponsor

Merck Sharp & Dohme LLC

Industry

Registry information

Official study title

A Multiple Dose Study to Evaluate Safety, Tolerability, PK, and Effect of MK-1167 on QTc in Healthy Adult Participants

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Dec 5, 2025
Registry last updated
Apr 28, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.